International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Lung cancer; Biomarkers; Non-small cell lung cancer (NSCLC); Small cell lung cancer (SCLC)

Introduction

Lung cancer is a major global health challenge and remains one of the most prevalent and deadly forms of cancer worldwide. Accounting for approximately 18% of all cancer deaths, lung cancer's high mortality rate is primarily due to the fact that it is often diagnosed at advanced stages when curative treatment options are limited. The two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), exhibit distinct biological behaviors and responses to treatment. NSCLC which constitutes about 85% of lung cancer cases includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. SCLC, on the other hand, is less common but more aggressive and fast-growing [1].

Early detection of lung cancer is crucial for improving survival rates, as the prognosis is significantly better when the disease is identified at an early stage. However, the majority of patients are diagnosed when the cancer has already metastasized. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in sensitivity, specificity, and invasiveness. This has spurred extensive research into the development of biomarkers-biological molecules found in blood, other body fluids, or tissues-that can indicate the presence of cancer [2].

Biomarkers have emerged as powerful tools in the fight against lung cancer, offering potential not only for early detection but also for prognosis and personalized treatment strategies. These biomarkers can provide critical information about the molecular characteristics of a tumor, guiding therapeutic decisions and monitoring disease progression and response to treatment. This article explores the recent advances in lung cancer biomarkers, focusing on their detection methodologies, clinical applications, and future potential in improving patient outcomes. Through a comprehensive review of the current state of lung cancer biomarkers, we aim to highlight their significance in transforming lung cancer management and outline the challenges and future directions in this rapidly evolving field.

Discussion

Types of lung cancer biomarkers

Diagnostic biomarkers: These biomarkers aid in the early detection of lung cancer. Examples include circulating tumor cells (CTCs), cell-free DNA (cfDNA) and specific protein markers like carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1). Techniques such as liquid biopsy have made it possible to detect these markers non-invasively [3].

Prognostic biomarkers: These markers help predict the likely course of the disease. EGFR mutations, ALK rearrangements, and KRAS mutations are notable examples in NSCLC. Their presence can indicate disease aggressiveness and potential response to therapies.

Predictive biomarkers: These biomarkers predict the likely response to specific treatments. PD-L1 expression levels, for instance, are used to identify patients who may benefit from immune checkpoint inhibitors. Similarly, mutations in the EGFR gene can predict the efficacy of tyrosine kinase inhibitors (TKIs) [4].

Detection methodologies

Liquid biopsy: This non-invasive method involves analyzing blood samples to detect CTCs, cfDNA and exosomes. It provides a real-time snapshot of the tumor's genetic landscape and can be used for monitoring disease progression and treatment response [5].

Next-generation sequencing (NGS): NGS allows for comprehensive genomic profiling of tumors, identifying multiple mutations simultaneously. This technology has been instrumental in uncovering actionable genetic alterations in lung cancer.

Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH): These traditional techniques remain vital for detecting protein expressions and gene rearrangements in tissue samples, respectively [6].

Clinical applications

Early detection: Biomarkers like CTCs and cfDNA enable the early detection of lung cancer, potentially before clinical symptoms appear [7]. Early-stage detection significantly improves survival rates and allows for more effective interventions.

Prognosis and monitoring: Prognostic biomarkers provide insights into disease progression and patient outcomes. Regular monitoring of these biomarkers can help track treatment effectiveness and detect recurrence.

Personalized treatment: The identification of specific genetic mutations and protein expressions allows for tailored treatment approaches. For instance, patients with EGFR mutations may benefit from TKIs, while those with high PD-L1 expression levels may respond better to immunotherapy [8].

Challenges and future directions

Technical limitations: Despite advancements, technical challenges remain in biomarker detection, including sensitivity, specificity, and standardization of assays.

Cost and accessibility: High costs and limited access to advanced diagnostic technologies can restrict the widespread use of biomarker testing, particularly in low-resource settings [9].

Emerging biomarkers: Research is ongoing to identify new biomarkers and validate their clinical utility. Advances in artificial intelligence and machine learning are expected to enhance biomarker discovery and interpretation [10].

Conclusion

The field of lung cancer biomarkers has seen significant progress, with advancements in detection methodologies and clinical applications offering new hope for patients. Early detection, accurate prognosis, and personalized treatment strategies made possible by these biomarkers have the potential to transform lung cancer management. Continued research and technological innovations are essential to overcome current challenges and fully realize the potential of lung cancer biomarkers in improving patient outcomes.

Acknowledgement

None

Conflict of Interest

None

References

1. McKay RR, Bossé D, Choueiri TK (2018) Evolving Systemic Treatment Landscape for Patients with Advanced Renal Cell Carcinoma. J Clin Oncol 36:615-623.

Indexed at, Google Scholar, Crossref

2. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, et al. (2016) Renal cell cancer histological subtype distribution differs by race and Sex. BJU Int 117:260-265.

Indexed at, Google Scholar, Crossref

3. Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Handb Clin Neurol 132:139-156.

Indexed at, Google Scholar, Crossref

4. Choueiri TK, Je Y, Cho E (2014) Analgesic use and the risk of kidney Cancer: A meta-analysis of epidemiologic studies. Int J Cancer 134:384-396.

Indexed at, Google Scholar, Crossref

5. Moore LE, Boffetta P, Karami S, Brennan P, Stewart PS, et al. (2010) Occupational trichloroethylene exposure and renal carcinoma risk: Evidence of genetic susceptibility by reductive metabolism gene variants. Cancer Res 70:6527-6536.

Indexed at, Google Scholar, Crossref

6. Weikert S, Boeing H, Pischon T, Olsen A, Tjonneland A, et al. (2006) Fruits and vegetables and renal cell carcinoma: Findings from the European prospective investigation into Cancer and nutrition (epic). Int J Cancer 118:133-139.

Indexed at, Google Scholar, Crossref

7. Oto J, Fernández-Pardo Á, Roca M, Plana E, Solmoirago MJ, et al. (2020) Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study. J Proteom 218: 723.

Indexed at, Google Scholar, Crossref

8. Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, et al. (2010) Fibronectin 1 mrna expression correlates with advanced disease in renal Cancer. BMC Cancer 10:503.

Indexed at, Google Scholar, Crossref

9. Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, et al. (2014) Maldi imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics 14:924-935.

Indexed at, Google Scholar, Crossref

10. Lee HO, Uzzo RG, Kister D, Kruger WD (2017) Combination of serum histidine and plasma tryptophan as a potential biomarkerto detect clear cell renal cell carcinoma. J Transl Med 15:72.

Indexed at, Google Scholar, Crossref